Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Inclusion Criteria: * (1) Age≥ 18 years old, gender is not limited; * (2) expected survival time≥ 3 months; * (3) ECOG score 0-1 points; * (4) Acute myeloid leukemia was clearly diagnosed during screening, and tumor cells were positive for B7-H3 expression; * (5) Subjects with relapsed/refractory acute myeloid leukemia who have failed standard treatment or lack effective treatment methods. * (6) Coagulation function, liver and kidney function, cardiopulmonary function meet requirements. * (7) Be able to understand the trial and have signed the informed consent form. Exclusion Criteria: * (1) Malignant tumors other than acute myeloid leukemia within 5 years before screening; * (2) Those who test positive for virus and syphilis; * (3) Severe heart disease: including but not limited to unstable angina, myocardial infarction (within 6 months before screening), congestive heart failure (New York Heart Association \[NYHA\] classification≥ grade III), severe arrhythmia; * (4) Unstable systemic diseases judged by the investigator: including but not limited to severe liver, kidney or metabolic diseases requiring drug treatment; * (5) Active infection or uncontrollable infection requiring systemic treatment within 7 days prior to screening; * (6) pregnant or lactating women, female subjects who planned to become pregnant within 2 years after cell reinfusion or male subjects whose partners planned to become pregnant within 2 years after their cell reinfusion; * (7) Subjects who were receiving systemic steroid therapy within 7 days prior to the year or who were judged by the investigator to require long-term systemic steroid therapy during treatment (other than inhalation or topical use); * (8) Have participated in other clinical studies within 1 month before screening; * (9) There was evidence of central nervous system invasion during subject screening, such as tumor cells detected in cerebrospinal fluid or imaging showing central infiltration; * (10) Those who have graft-versus-host response and need to use immunosuppressants; * (11) Those with a history of epilepsy or other central nervous system diseases; * (12) Patients with primary immunodeficiency diseases; * (13) situations that other investigators consider unsuitable for enrollment.